These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20079230)

  • 1. [Secondary prophylaxis of invasive fungal infection in haematopoietic stem cell recipients].
    Xu LP; Tang FF; Liu DH; Liu KY; Chen H; Chen YH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2009 Oct; 48(10):853-6. PubMed ID: 20079230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
    Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
    Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic SCT in patients with a history of invasive fungal infection.
    Zhang P; Song A; Wang Z; Feng S; Qiu L; Han M
    Bone Marrow Transplant; 2009 Apr; 43(7):533-7. PubMed ID: 19104496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
    Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical characteristic and risk factors for the incidence of invasive fungal infection in patients following allogeneic hematopoietic stem cell transplantation].
    Zhang Y; Liu C; Liu QF; Sun J; Fan ZP; Xu D; Jiang QL
    Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(40):2814-7. PubMed ID: 20137659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary antifungal prophylaxis in pediatric hematopoietic stem cell transplants.
    Azik FM; Tezer H; Ozkaya-Parlakay A; Aksu T; Bayram C; Fettah A; Tavil B; Tunç B
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e19-22. PubMed ID: 25522351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
    Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
    Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
    Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
    J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
    Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
    J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Itraconazole for secondary prophylaxis of invasive fungal infection in patients undergoing chemotherapy and stem cell transplantation].
    Shi JM; Wang C; Zhou YH; Yu K; Du X; Luo Y; Cai Z; He JS; Ye XJ; Zhang J; Xie WZ; Huang H
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):413-6. PubMed ID: 23688752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens.
    Corzo-León DE; Satlin MJ; Soave R; Shore TB; Schuetz AN; Jacobs SE; Walsh TJ
    Mycoses; 2015 Jun; 58(6):325-36. PubMed ID: 25808822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
    Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
    Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients.
    Allinson K; Kolve H; Gumbinger HG; Vormoor HJ; Ehlert K; Groll AH
    J Antimicrob Chemother; 2008 Mar; 61(3):734-42. PubMed ID: 18238891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
    Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
    Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.
    Liu M; Li Y; Zhang Y; Zhao X; Zhai B; Zhang Q; Wang L; Zhao Y; Li H; Wang Q; Gao C; Huang W; Yu L
    PLoS One; 2014; 9(12):e115461. PubMed ID: 25531544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy.
    Grigull L; Kuehlke O; Beilken A; Sander A; Linderkamp C; Schmid H; Seidemann K; Sykora KW; Schuster FR; Welte K
    Pediatr Transplant; 2007 May; 11(3):261-6. PubMed ID: 17430480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT.
    El-Cheikh J; Venton G; Crocchiolo R; Fürst S; Faucher C; Granata A; Oudin C; Coso D; Bouabdallah R; Vey N; Duran S; Fougereau E; Berger P; Chabannon C; Blaise D
    Bone Marrow Transplant; 2013 Nov; 48(11):1472-7. PubMed ID: 23749104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prophylaxis use of posaconazole (P) in an hemato-oncology unit: a retrospective study].
    Selvy N; Villiet M; Hansel-Esteller S
    Pathol Biol (Paris); 2010 Apr; 58(2):123-6. PubMed ID: 19864087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion.
    Sun YQ; Xu LP; Liu DH; Zhang XH; Chen YH; Chen H; Ji Y; Wang Y; Han W; Wang JZ; Wang FR; Liu KY; Huang XJ
    Clin Microbiol Infect; 2012 Oct; 18(10):997-1003. PubMed ID: 22085092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis.
    Liu Q; Lin R; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Fan Z; Zhou H; Jiang Q; Zhang F; Zhai X; Xu D; Wei Y; Song J; Li Y; Feng R
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1198-203. PubMed ID: 24769013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.